Impact of the Microbiota on the Likelihood of Renal Graft Rejection

Launched by INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FRANCE · Jan 29, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating how the gut bacteria in our bodies may affect the likelihood of kidney transplant rejection. The researchers are specifically looking for a certain bacterial pattern in the blood or stool of patients who have received a kidney transplant and are being treated with a medication called Nulojix during their first year after the transplant. By identifying this bacterial signature, they hope to better understand and predict when a transplant might be rejected.

If you are interested in participating, you must be scheduled for a kidney transplant and will be receiving specific treatments that include Simulect and Nulojix, along with other medications. The trial is open to people aged between 65 and 74 years or 25 and 66 years, and anyone can join regardless of gender. However, certain conditions like having multiple transplants, current infections, or being pregnant may prevent you from participating. If you join, you can expect to provide blood or stool samples to help researchers gather the needed information. It’s important to note that your participation could contribute to improving care for future kidney transplant patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients called for a kidney transplant
• • Induction therapy with Simulect, maintenance therapy with Nulojix, mycophenolate acid and steroids
• • Patient having signed the informed consent
• Exclusion Criteria:
• • Multiple grafts combined or sequential
• • Induction therapy with polyclonal antibodies
• • HIV or active viral infection such as hepatitis B or C
• • Active bacterial infection
• • Pregnancy or breastfeeding at time of inclusion
• • Patient unable to express their consent